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Background. Individuals with a family history of colorectal cancer (CRC) have an increased risk of CRC.We evaluated the diagnostic
yield of CCE in the detection of lesions and also two different colon preparations. Methods. A prospective multicenter study was
designed to assess CCEdiagnostic yield in a cohort of asymptomatic individuals with a family history of CRC.CCE and colonoscopy
were performed on the same day by 2 endoscopists who were blinded to the results of the other procedure. Results. Fifty-three
participants were enrolled. The sensitivity, specificity, PPV, and NPV of CCE for detecting advanced adenomas were 100%, 98%,
67%, and 100%. Sensitivity, specificity, PPV, and NPV of CCE for the diagnosis of individuals with polyps were 87%, 97%, 93%,
and 88%, respectively. CCE identify 100% of individuals with significant or advanced lesions. Overall cleanliness was adequate by
60.7% of them. The PEG-ascorbic boost seems to improve colon cleanliness, with similar colonic transit time. Conclusion. CCE
is a promising tool, but it has to be considered as an alternative technique in this population in order to reduce the number of
colonoscopies performed.More studies are needed to understand appropriate screening follow-up intervals and optimize the bowel
preparation regimen.
1. Introduction
Most colorectal cancer (CRC) cases are sporadic but familial
clustering is found in 25%. It is well known that the risk
of developing CRC is 2 to 4-fold higher in individuals with
a family history of CRC than in the general population,
depending on the number of cases of CRC in the family
and how closely the individuals are related [1]. A recent
Chinese study [2] has also shown that the prevalence of
advanced neoplasm (defined as CRC or adenoma of at least
10mm with high-grade dysplasia or villous component in
histology) is higher in the siblings of patients with CRC
than in controls (7.5% versus 2.9%, odds ratio [OR] 3.07,
𝑃 < 0.05). Thus, in this group of high-risk individuals, it
is recommended that screening begin at an earlier age and
be conducted with increased frequency [2]. For instance,
screening in individuals with a first-degree relative diagnosed
with CRC before the age of 60 years or in persons with 2 or
more cases in the family diagnosed at any age should begin
at the age of 40 years or 10 years before the age at diagnosis
of the relative. The current recommendation for this group
is to perform CRC screening with colonoscopy every 5 years
[2–4].
However, colonoscopy, which is considered the gold
standard, has some limitations that may affect compliance.
One of them is perception of the test, which varies by country,
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Table 1: Study protocol: colon preparation.
Clear liquid diet
Day 1
12:00 p.m. 200 g carbohydrates + water
17:00 p.m. 200 g carbohydrates + water
19–21:00 p.m. 1 liter PEG + ascorbic + water
Day 0
7:00 a.m. 1 liter PEG + ascorbic + water
9:00 a.m. 10mg metoclopramide
9:30 a.m. Capsule ingestion
10:00 a.m. 1∘ boost- 2/3 l. PEG + ascorbic + water or Sodium Phosphate∗
13:00 p.m. 2∘ boost- 1/3 l. PEG + ascorbic + water or sodium phosphate (3 hours after first boost).Ψ
Suppository
17:00 PM p.m. Colonoscopy
∗(30 minutes after pylorus pass checked by RAPID real-time viewer).
ΨIf capsule was not excreted.
ethnicity, and socioeconomic status. Recent published data
from amulticenter study showed that colonoscopy participa-
tion rate in a population screening program was only 24.6%
[5]. The risk of potential complications is another limitation.
Rate of perforation after a diagnostic colonoscopy is very low
(1/1000 patients) but exists [6].
Another important drawback of colonoscopy is the risk
of missed lesions, which, according to a recent study, occurs
in 2% to 26% cases [7]. Studies also suggest that colonoscopy
may not be as sensitive in the right colon as it is in the left
colon [8, 9]. Then other alternatives have been explored [10].
Colon capsule endoscopy (CCE) allows visualization
of the colon mucosa without the need for sedation and
insufflation. Since its introduction in 2006, this procedure
has demonstrated to be safe and well-tolerated [10–17].
CCE has emerged as a potential cost-effective alternative
to colonoscopy because it may improve adherence to CRC
screening programs, although this has not been demon-
strated yet [18]. Therefore, the objective of this study was
to assess the diagnostic yield of CCE in the detection of
significant colonic lesions (polyps and cancer) in individuals
with a family history of CRC and to compare the efficacy of
two different colon preparations.
2. Patients and Methods
2.1. Study Group. Individuals with CRC familial history
were recruited from colonoscopy screening schedules. The
protocol was approved by the Ethics Committee of Hospital
Clinic and participants gave informed consent.
Participants were prospectively enrolled from January
2009 to January 2011 in 2 tertiary hospitals in Barcelona.
CCE and colonoscopy were performed on the same day by 2
different endoscopists who were blinded to the results of the
other examination.
Inclusion criteria included asymptomatic individuals
with a first-degree relative diagnosed with CRC before the
age of 60 years or with 2 or more relatives diagnosed with
CRC at any age. Exclusion criteria were previous history of
colonic lesions (polyps and/or neoplasia, inflammatory bowel
disease, polyposis syndromes, or Lynch syndrome), severe
heart failure or renal failure, dysphagia, suspicion of intestinal
obstruction, or pregnancy.
2.2. CCE. CCEwas performed using the first-generation Pill-
cam Colon capsule (Given Imaging, Israel) which measures
31 × 11mm and acquires images at a rate of 4 frames per
second. All capsule videos were read by 2 physicians with
expertise in this technique. A dissolvable capsule (Agile
Patency Capsule, Given Imaging) was administered prior to
the procedure in case of major previous intestinal surgery,
chronic use of nonsteroidal anti-inflammatory drugs, or
abdominal pain to rule out stenosis. Exploration was consid-
ered completewhen hemorrhoids plexuswere seen or capsule
was excreted before colonoscopy.
2.3. Colon Preparation. Preparation started the day before
with a diet consisting of liquids and carbohydrates (plain
noodles cooked in salt water) at lunch time in order to
increasemotility. At night and the nextmorning, participants
ingested a low-volume preparation containing polyethylene
glycol (PEG) plus ascorbic acid in split dose (Moviprep)
(Table 1). As boosters they took PEG + ascorbic (group 1)
or sodium phosphate (group 2) in order to compare colon
cleanliness and transit time.
Similarly to previous studies, a 4-point scale grading
system for the evaluation of colon preparation was used
[11]. Colon cleanliness was scored as excellent (no more
than small pieces of adherent feces), good (small amount
of feces or dark fluid but not enough to interfere with the
examination), fair (enough feces or dark fluid present to
preclude a completely reliable examination), or poor (large
amount of faecal residue) in 5 segments (cecum, ascending,
transverse, descending-sigmoid, and rectum). An overall
colon cleansing grade was also evaluated by using the same
grading system. It was considered an adequate preparation
when excellent or good and inadequate if fair or poor.
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2.4. Colonoscopy (Gold Standard). Colonoscopy was per-
formed in the afternoon, between 8 and 10 hours after capsule
ingestion, under sedation (midazolam or propofol at the
physician’s discretion). Cleansing was graded upon colon
withdrawal for each segment after completion of washing
with the Boston Bowel Preparation [19]. Polyps detected
during colonoscopy were removed and sent for histological
assessment. If the capsule was seen during colonoscopy, it was
retrieved.
Significant polyps were considered as those with size
≥6mm. Advanced adenomas were considered those≥10mm,
with villous histology or high-grade dysplasia. When a polyp
was identified by CCE but not in colonoscopy, the patient was
rescheduled for a second colonoscopy. False positives were
defined as lesions detected only by CCE, after 2 consecutive
colonoscopies.
2.5. Satisfaction Level. A patient satisfaction questionnaire
consisting of 3 questions was done telephonically one month
later. Patients were asked to evaluate their degree of satisfac-
tion with the CCE and colonoscopy procedures using a 5-
point subjective scale (from poor to excellent).
2.6. Statistical Analysis. Sample size was calculated assuming
that CCE would detect the same number of lesions than
colonoscopy, giving a total of 51 patients, with a significance
level of 5%, statistical power of 80% assuming 10% of dropout
rate.
Performance characteristics and 95% CI were calcu-
lated for any-sized polyps and for polyps 6mm or larger.
Descriptive statistics for continuous variables are expressed
as mean and standard error and categorical variables as
percentage. A two-sided Student’s 𝑡-test was used to compare
continuous variables, and the 𝜒2 test was applied to compare
categorical variables. Statistical analysis was performed with
SPSS software, version 19.0.
3. Results
A total of 53 participants were eligible for inclusion but two
were excluded because of technical CCE failure and incom-
plete colonoscopy, respectively. Therefore, 51 participants
were included and data analyzed: 27 in group 1 (boosters
with ascorbic) and 24 in group 2 (boosters with sodium
phosphate). Eighteen individuals (35.2%) had a total of 51
polyps. Demographic characteristics of the participants are
shown in Table 2. Characteristics of the lesions detected by
colonoscopy and CCE are shown in Table 3.
Capsule Agile Patency was administered to 4 patients
confirming intestinal permeability and CCE was ingested
without problem.
3.1. Per Individuals Analysis. CCE detected polyps in 15
individuals (29.4%). In four patients in whom CCE was
normal and colonoscopy detected lesions, all of them were
nonsignificant lesions. One of them had poor preparation
and 5 polyps were missed and the other 3 subjects had good
preparation and 4 polyps were missed. Histological analysis
Table 2: Demographic characteristics of the population.
Sex (M/F), 𝑛 (%) 23 (43.1%)/28 (56.9%)
Age (years), mean (SD) 48.6 (8.9)
NSAIDs or anticoagulant therapy, 𝑛 (%) 7 (13.7%)
Relatives with CRC, mean (SD) 1.42 (0.54)
First degree relative, 𝑛 (%) 33 (64.7%)
Two or more relatives with CRC, 𝑛 (%) 18 (39.6%)
Age at diagnosis of CRC (years), mean (SD) 56.8 (1.8)
of these lesionswas tubular adenoma (𝑛 = 3) andhyperplastic
polyps (𝑛 = 6).
Sensitivity, specificity, PPV, and NPV of CCE for the
detection of individuals with polyps of any size were 87%,
97%, 93%, and 88% respectively. Remarkably, when we
analyzed only subjects with significant or advanced lesions,
CCE identified all of them.
3.2. Per Polyps Analysis. CCE detected 38 polyps and
colonoscopy 51 polyps. Four polypswere seen byCCEandnot
in the first colonoscopy. However, the second colonoscopy
found a 4mm polyp that was removed and the other 3 were
considered false positives. Therefore, 17 polyps in 8 individ-
uals were missed by CCE. All of them were nonsignificant
lesions. 14 of these polyps were hyperplastic and 3 were
tubular adenoma.None of themissed polyps showed a villous
component or high-grade dysplasia.
The diagnostic yield, sensitivity, specificity, PPV, and
NPV of CCE are shown in Table 4. No cases of CRC were
diagnosed.
Potential factors associated with missed polyps including
complete examination with CCE, CCE cleanliness, type of
booster, or location of polyps were included in an univariate
analysis. Only location was a significant risk factor from
univariate andwas included in amultivariate analysis. Finally,
the only independent predictor formissed polyps in our study
was location in the left colon, rectum essentially (OR 0.4;
𝑝 < 0.001).
3.3. Excretion Rate and Colon Cleanliness. The mean transit
time from mouth to the anus was 251.0 ± 17.9min.
CCEwas excretedwithin 10 hours of ingestion in 84.3% of
the participants. Patients of group one had a shorter colonic
transit time (128,5 ± 95.6 versus 166.8 ± 121 minutes, pNS).
CCE examination was complete in 44 individuals (87%) and
incomplete in 7 cases (13%; 6 in group 1 and only 1 in group
2); in these cases capsule was retrieved during colonoscopy in
the rectosigmoid area in 5 participants and in the cecum in 2
of them.
Overall cleanliness was excellent or good in 60.7% of CCE
examinations (70.3% in group 1 and 50% in group 2, 𝑝 = 0.1)
(Figure 1). Colon cleanliness was graded better in the group
of PEG + ascorbic boost compared to the cleanliness in the
sodium phosphate boost group but this difference was not
statistically achieved.
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Table 3: Characteristics of the polyps found in CCE and colonoscopy.
Individuals Booster Cleanness in colonsegments CCE polyps Colonoscopy polyps Histology
(1) PEG-Asc Good 10mm sigmoid 10mm sigmoid Tub-vell
(2) NaP Good 8mm descending colon3mm sigmoid
8mm descending colon
3mm sigmoid Tubular adenoma
(3) NaP ExcellentGood
10mm cecum
5mm sigmoid
12mm cecum
5mm sigmoid Tubular adenoma
(4) PEG.Asc
Fair 8mm descending colon 7mm transverse colon
Tubular adenoma
Fair 5mm descending colon 5mm sigmoid
Poor 8mm sigmoid 4mm rectum
Fair 10mm sigmoid 7mm recto
Fair 4mm recto 4mm recto
3mm recto 4mm recto
(5) PEG.Asc Excellent 3 mm recto 4mm recto Tubular adenoma
(6) PEG Asc Fair
—
3mm sigmoid
—
5mm transverse
3mm recto
3mm recto
Tubular adenoma
(7) NaP Excellent
3mm sigmoid
3mm sigmoid
3mm sigmoid
4mm sigmoid
2mm recto
3mm recto
3mm sigmoid
3mm sigmoid
2mm sigmoid
3mm recto
3mm recto
2mm recto
Hyperplastic
(8) NaP Good
3mm recto 2mm recto
Hyperplastic— 2mm recto
— 2mm recto
(9) NaP Good
6mm descending —
Hyperplastic5mm descending —
3mm recto 3mm sigmoid
(10) NaP Good 2mm recto 2mm recto Hyperplastic
(11) NaP Good
3mm descending
—
—
2mm recto
2mm descending
2mm descending
2mm descending
2mm recto
Hyperplastic
(12) NaP Good 4mm sigma 5mm sigma Tubular adenoma
(13) PEG Asc Poor 5mm descending2mm descending
—
—
(14) PEG Asc Good
2mm transverse
2mm descending
2mm descending
7mm sigmoid
3mm ascending
3mm transverse
2mm sigmoid
5mm sigmoid
Tubular adenoma
Tubular adenoma
Hyperplastic
Tubular adenoma
(15) NaP Fair
5mm ascending
4mm descending
—
—
3mm ascending
5mm sigmoid
4mm sigmoid
2mm sigmoid
Tubular adenoma
(16) PEG Asc Good — 3mm sigmoid Tubular adenoma
(17) NaP Poor
—
—
—
—
5mm transverse
2mm recto
3mm recto
2mm recto
Tubular adenoma
Hyperplastic
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Table 3: Continued.
Individuals Booster Cleanness in colonsegments CCE polyps Colonoscopy polyps Histology
(18) NaP Excellent ——
3mm recto
3mm recto
∗
(19) PEG Asc Good — 3mm sigmoid Hyperplastic
∗Unrecovered polyps.
Table 4: Diagnostic yield of colon capsule endoscopy for detection polyps.
Prevalence (%) Sensitivity% (95% IC) Specificity% (95% IC) PPV% (95% IC) NPV% (95% IC)
Polyps
Any size 51 (74%) 66 (61–97) 100 100 89 (79–99)
≥6mm 4 (7.8) 100 96 (90–100) 67 (29–100) 100
≥10mm 2 (3.9) 100 98 (94–100) 67 (29–100) 100
Adenoma
Any size 12 (23.5) 83 (62–100) 100 100 95 (89–100)
≥6mm 4 (7.8) 100 98 (94–100) 67 (29–100) 100
≥10mm 2 (3) 100 98 (94–100) 67 (29–100) 100
Advanced adenoma
Any size 2 (3.8) 100 98 (94–100) 67 (29–100) 100
≥6mm 2 (3.8) 100 98 (94–100) 67 (29–100) 100
≥10mm 2 (3.8) 100 98 (94–100) 67 (29–100) 100
CRC 0
0
5
10
15
20
Excellent Good Fair Bad Acceptable Nonacceptable
PEG + ascorbic
Sodium phosphate
Figure 1: Number of patients with acceptable preparation in capsule
endoscopy with different boosters (𝑝 = 0.1).
3.4. Safety and Tolerability. There were no adverse effects
related to CCE, colonoscopy or bowel preparation. Only 31
out of 51 subjects answered the satisfaction questionnaire.
CCE was evaluated as excellent, very good, or good in 100%
of participants, while 16% of them evaluated colonoscopy as
fair-bad.Overall, 70.9%of participants submitted to the ques-
tionnaire preferred CCE, while 29% preferred colonoscopy
(Figure 2).
4. Discussion
In this prospective, multicenter study specifically designed
to assess CCE diagnostic yield in asymptomatic subjects
with a family history of CRC, we can conclude that CCE is
an accurate, feasible, well-tolerated, and safe alternative for
this CRC high-risk population. CCE was able to identify all
the individuals with significant polyps, using a low-volume
preparation regimenwith very good tolerance and acceptable
cleanliness level. Most important target is to identify patients
Excellent Very good Good Fair Bad
CCE
Colonoscopy
0
5
10
15
20
25
30
Figure 2: Patients satisfaction level (%) with colon capsule and
colonoscopy.
to be submitted to colonoscopy (with any significant polyp),
with a noninvasive test. This strategy could be accepted for a
higher number of subjects.
Sacher-Huvelin et al. analyzed a cohort of 545 patients
at average risk (𝑛 = 163) or increased risk of CRC
(𝑛 = 376) and described a low overall sensitivity for polyp
detection, probably due to poor colon cleanliness [17]. Gay
et al. also analyzed 128 individuals with any indication for
colonoscopy (76% with excellent or good preparation) and
showed sensitivity for CCE of 87.5% [16]. Our results are in
line with more recent studies that have shown that CCE is as
effective as colonoscopy for detecting significant lesions [20–
23].
The role of colon capsule endoscopy is still unclear
and it seems a contradiction to use an alternative tech-
nique in a high-risk population because colonoscopy is our
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gold standard. However, most of these colonoscopies, about
70%, will be negative and we could use other noninvasive
alternatives in order to select individuals with polyps for
a therapeutic colonoscopy. With this strategy we would
perform colonoscopy only in patients with significant lesions
and avoid a lot of unnecessary explorations. Otherwise, in
our study from 51 subjects included, 18 (35%) had lesions in
colonoscopy and only 4 (7%) had significant lesions. CCE
identified all of these patients with significant lesions. This
could have a positive impact on waiting colonoscopy lists
and reduce the care burden of the endoscopy units. On the
other hand, less colonoscopy implies less complication. We
think that all of these can make the CCE a cost-effective
alternative. A great option in CCE will be a same-day CCE
and colonoscopy if the patient has polyps, avoiding two colon
preparations, but this is logistically difficult for the moment
as Adria´n-de-Ganzo et al. hypothesize recently [18].
CCE is a well-tolerated exploration and probably its
use could increase colorectal cancer screening adherence
although this has not yet been demonstrated [23]. Satisfac-
tion level is another key feature in adherence to screening
programs. In our study 70% of subjects preferred CCE for
screening method. The results of the subjective assessment
questionnaire showed that CCE was rated higher than
colonoscopy and was perceived as good, very good, or excel-
lent by all patients. In addition, we found that individuals
would prefer to repeat CCE rather than colonoscopy for
surveillance purposes. Again, we have data about a small
number of patients and more studies have to be done.
Colon cleanliness is a crucial aspect related to sensitivity
of CCE. Colon preparation usually consists in the adminis-
tration of a clear liquid diet and a combination of laxatives
and prokinetic agents [24]. We used a new low-volume
solution consisting of PEG associated with ascorbic acid.
This preparation has recently been evaluated with adequate
results, achieving excellent or good cleanliness in >80% of
patients [25]. In our study, however, overall excellent or good
cleanliness was achieved in 60.7% of the patients (70.3% in
patients in group 1, MoviPrep booster). Patient tolerance of
this preparation was good and the procedure was classified as
easier for the participants since a low volume of liquid was
ingested. Also we found that PEG + ascorbic boost seems
to improve overall colon cleanliness compared to sodium
phosphate boost but we have a small size of patients need
more studies in order to optimize colon capsule preparation.
More studies are needed to investigate the long-term
follow-up of these individuals, as they are at higher risk
of CRC and small polyps can be missed. It is unknown
whether persons with familial risk might have faster growth
and progression of polyps. Only one study has evaluated the
cost-effectiveness of CCE in these persons, using a computer
model, and concluded that cost-effectiveness dependsmainly
on the ability of the procedure to improve adherence to CRC
screening [24].
The limitation of this study is that it was performed
with a first-generation capsule endoscopy. Recently, a second-
generation capsule, Pillcam Colon 2, has been developed,
which has higher sensitivity and obtains better results in the
detection of colonic lesions [21]. The main studies published
with first-generation CCE [10, 12, 13] reported sensitivities
of 63–88% and specificities of 64–94% in the detection of
colonic lesions with high NPVs. Two recent meta-analyses
with 626 patients and 837 patients, respectively, found sensi-
tivities for significant polyps of 69–76%, with specificities of
86% and 82% [20, 22]. In our study, CCE detected 4 polyps
that were missed on colonoscopy and repeat colonoscopy
confirmed only 1 of them as a true positive result.The remain-
der was confirmed as false positives of CCE. Assessment
of polyp size can also lead to confusion. In this respect,
the second-generation capsule is an important new advance
that allows measurement of polyp size, which will probably
decrease the number of false-positive results but not make
them disappear completely [26].
In conclusion, CCE is a promising tool that should be
considered as an alternative technique in the screening of
patients with familial colorectal cancer in order to reduce
the number of colonoscopies performed. More studies are
needed to understand appropriate screening follow-up inter-
vals and optimize the bowel preparation regimen.
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